Previous close | 4.1000 |
Open | 4.0500 |
Bid | 0.0000 x 1400 |
Ask | 0.0000 x 800 |
Day's range | 3.9800 - 4.1881 |
52-week range | 2.3300 - 9.7500 |
Volume | |
Avg. volume | 61,101 |
Market cap | 47.638M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.4600 |
Earnings date | 12 Nov 2021 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 20.75 |
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of -22.86% and 46.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Gain Therapeutics, Inc. (GANX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.65% and 25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?